Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05137262
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 45
- Registration Number
- NCT05128630
- Locations
- 🇮🇹
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- You Lu
- Target Recruit Count
- 30
- Registration Number
- NCT05092412
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, He Nan, China
🇨🇳West China Hospital Sichuan University, Chengdu, Si Chuan, China
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 49
- Registration Number
- NCT05068232
- Locations
- 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 194
- Registration Number
- NCT05061134
- Locations
- 🇬🇧
Research Site, Northwood, United Kingdom
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT05061550
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 147
- Registration Number
- NCT05043090
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Beijing Haidian Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05034133
- Locations
- 🇨🇳
Beijing Haidian Hospital, Beijing, China
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
- Conditions
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Davendra Sohal
- Target Recruit Count
- 30
- Registration Number
- NCT05027425
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Simmons Comprehensive Cancer Center UT Southwestern Medical Center, Dallas, Texas, United States
Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT05000710
- Locations
- 🇮🇱
Sheba Medical Centre, Ramat Gan, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.